Compare IHT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | XGN |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 71.2M |
| IPO Year | 1995 | 2014 |
| Metric | IHT | XGN |
|---|---|---|
| Price | $1.40 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 7.7K | ★ 437.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,600,000.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $2.59 |
| 52 Week High | $4.24 | $12.23 |
| Indicator | IHT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 72.80 | 66.56 |
| Support Level | $1.37 | $2.68 |
| Resistance Level | $1.51 | $6.75 |
| Average True Range (ATR) | 0.07 | 0.37 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 86.50 | 97.08 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.